To determine the effectiveness of intralesional 5-fluorouracil in objectively reversing hypertrophic scars in the periocular region resulting from trauma or cosmetic surgery.

During the initial visit, informed consent will be obtained and documented, alongside baseline photographs and measurements of the facial scar dimensions using a ruler. In the subsequent visits-second, third, fourth, and fifth-0.5 ml of intralesional 5-fluorouracil, diluted to 25 mg/ml, will be administered. Clinical photographs will be captured, and dimensions will be measured at each of these visits. A total of 0.5 ml of this solution will be injected weekly into the lesion to be treated, amounting to four doses over the course of one month.

Inclusion Criteria:

• Male or female participants aged ≥18 years.
• Presence of a facial scar in the periocular region secondary to trauma or facial cosmetic surgery.
• Ability and willingness to provide written informed consent.
• Signed informed consent form prior to participation.

Exclusion Criteria:

• Presence of active local infection in the periocular region.
• Active inflammatory dermatologic or ocular disorders in the treatment area.
• Known allergy or hypersensitivity to 5-fluorouracil.
• Pregnancy or breastfeeding.
• Inability to comply with follow-up visits.
• Withdrawal of consent during the study.
• Development of significant local or systemic adverse reactions during the study period.

From November to December 2026